Macrocyclic proteasome inhibitors

Current Medicinal Chemistry

Volumn 18, Issue 33, 2011, Pages 5052-5060

  Krahn, D ^a   Ottmann, C ^b   Kaiser, M ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

Author keywords

Anticancer agent; Argyrin; Glidobactin; Macrocycle; Medicinal chemistry; Natural product; Proteasome inhibitor; Rational drug design; Syrbactin; Syringolin; TMC 95A

Indexed keywords

ARGYRIN A; ARGYRIN F; BORTEZOMIB; CEPAFUNGIN II; CYCLOSPORIN A; GLIDOBACTIN A; MACROCYCLIC COMPOUND; PHEPROPEPTIN; PROTEASOME; PROTEASOME INHIBITOR; SCYTONEMIDE A; SIOMYCIN A; SYCTONEMIDE A; SYRABACTIN; THIOSTREPTON; TMC 95A; TMC 95B; TMC 95C; TMC 95D; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BIOLOGICAL ACTIVITY; CANCER CHEMOTHERAPY; COMPETITIVE INHIBITION; DISEASE SEVERITY; DOWN REGULATION; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME SUBSTRATE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PSEUDOMONAS SYRINGAE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG DESIGN; HUMANS; MACROCYCLIC COMPOUNDS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES;

EID: 80054850810     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797636063     Document Type: Article

References (86)

1. Kisselev, A. F.; Goldberg, A. L. Proteasome inhibitors: From research tools to drug candidates. Chem. Biol., 2001, 8, 739-758. (Pubitemid 32752454)
2. Goldberg, A. L.; Rock, K. Not just research tools-proteasome inhibitors offer therapeutic promise. Nat. Med., 2002, 8, 338-340. (Pubitemid 34407027)
3. Voorhees, P. M.; Orlowski, R. Z. The proteasome and proteasome inhibitors in cancer therapy. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 189-213. (Pubitemid 43271188)
4. Orlowski, R. Z.; Kuhn, D. J. Proteasome inhibitors in cancer therapy: Lessons from the first decade. Clin. Cancer Res., 2008, 14, 1649-1657. (Pubitemid 351469448)
5. Groll, M.; Huber, R.; Moroder, L. The persisting challenge of selective and specific proteasome inhibition. J. Pept. Sci., 2009, 15, 58-66.
6. Naujokat, C.; Fuchs, D.; Berges, C. Adaptive modification and flexibility of the proteasome system in response to proteasome inhibition. Biochim. Biophys. Acta, 2007, 1773, 1389-1397. (Pubitemid 47374847)
7. Dick, L. R.; Fleming, P. E. Building on bortezomib: Second-generation proteasome inhibitors as anti-cancer therapy. Drug Discov. Today, 2010, 15, 243-249.
8. Driggers, E. M.; Hale, S. P.; Lee, J.; Terrett, N. K. The exploration of macrocycles for drug discovery-an underexploited structural class. Nat. Rev. Drug Discov., 2008, 7, 608-624. (Pubitemid 351927725)
9. Marsault, E.; Peterson, M. L. Macrocycles are great cycles: Applications, opportunities, and challenges of synthetic macrocycles in drug discovery. J. Med. Chem., 2011, 54, 1961-2004.
10. Groll, M.; Ditzel, L.; Lowe, J.; Stock, D.; Bochtler, M.; Bartunik, H. D.; Huber, R. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature, 1997, 386, 463-471. (Pubitemid 27164066)
11. Brannigan, J. A.; Dodson, G.; Duggleby, H. J.; Moody, P. C.; Smith, J. L.; Tomchick, D. R.; Murzin, A. G. A protein catalytic framework with an Nterminal nucleophile is capable of self-activation. Nature, 1995, 378, 416-419.
12. Baumeister, W.; Walz, J.; Zuhl, F.; Seemuller, E. The proteasome: Paradigm of a self-compartmentalizing protease. Cell, 1998, 92, 367-380. (Pubitemid 28093014)
13. Stadtmueller, B. M.; Hill, C. P. Proteasome activators. Mol. Cell, 2011, 41, 8-19.
14. Finley, D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu. Rev. Biochem., 2009, 78, 477-513.
15. Lin, G.; Li, D.; de Carvalho, L. P.; Deng, H.; Tao, H.; Vogt, G.; Wu, K.; Schneider, J.; Chidawanyika, T.; Warren, J. D.; Li, H.; Nathan, C. Inhibitors selective for mycobacterial versus human proteasomes. Nature, 2009, 461, 621-626.
16. Nussbaum, A. K.; Dick, T. P.; Keilholz, W.; Schirle, M.; Stevanovic, S.; Dietz, K.; Heinemeyer, W.; Groll, M.; Wolf, D. H.; Huber, R.; Rammensee, H. G.; Schild, H. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 12504-12509.
17. Groettrup, M.; Kirk, C. J.; Basler, M. Proteasomes in immune cells: More than peptide producers? Nat. Rev. Immunol., 2010, 10, 73-78.
18. Murata, S.; Sasaki, K.; Kishimoto, T.; Niwa, S.; Hayashi, H.; Takahama, Y.; Tanaka, K. Regulation of CD8+ T cell development by thymus-specific proteasomes. Science, 2007, 316, 1349-1353. (Pubitemid 46871657)
19. Dahlmann, B.; Ruppert, T.; Kuehn, L.; Merforth, S.; Kloetzel, P. M. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J. Mol. Biol., 2000, 303, 643-653.
20. Kloss, A.; Meiners, S.; Ludwig, A.; Dahlmann, B. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovasc. Res., 2010, 85, 367-375.
21. Gallastegui, N.; Groll, M. The 26S proteasome: Assembly and function of a destructive machine. Trends Biochem. Sci., 2010, 35, 634-642.
22. Schwartz, A. L.; Ciechanover, A. The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu. Rev. Med., 1999, 50, 57-74. (Pubitemid 29117052)
23. Sadre-Bazzaz, K.; Whitby, F. G.; Robinson, H.; Formosa, T.; Hill, C. P. Structure of a Blm10 complex reveals common mechanisms for proteasome binding and gate opening. Mol. Cell, 2010, 37, 728-735.
24. Bech-Otschir, D.; Helfrich, A.; Enenkel, C.; Consiglieri, G.; Seeger, M.; Holzhutter, H. G.; Dahlmann, B.; Kloetzel, P. M. Polyubiquitin substrates allosterically activate their own degradation by the 26S proteasome. Nat. Struct. Mol. Biol., 2009, 16, 219-225.
25. Hauske, P.; Ottmann, C.; Meltzer, M.; Ehrmann, M.; Kaiser, M. Allosteric regulation of proteases. Chembiochem, 2008, 9, 2920-2928.
26. Dahlmann, B. Role of proteasomes in disease. BMC Biochem., 2007, 8 Suppl 1, S3.
27. Borissenko, L.; Groll, M. 20S proteasome and its inhibitors: Crystallographic knowledge for drug development. Chem. Rev., 2007, 107, 687-717. (Pubitemid 46502369)
28. Tan, X.; Osmulski, P. A.; Gaczynska, M. Allosteric regulators of the proteasome: Potential drugs and a novel approach for drug design. Curr. Med. Chem., 2006, 13, 155-165.
29. Kuhn, D. J.; Hunsucker, S. A.; Chen, Q.; Voorhees, P. M.; Orlowski, M.; Orlowski, R. Z. Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors. Blood, 2009, 113, 4667-4676.
30. Muchamuel, T.; Basler, M.; Aujay, M. A.; Suzuki, E.; Kalim, K. W.; Lauer, C.; Sylvain, C.; Ring, E. R.; Shields, J.; Jiang, J.; Shwonek, P.; Parlati, F.; Demo, S. D.; Bennett, M. K.; Kirk, C. J.; Groettrup, M. A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat. Med., 2009, 15, 781-787.
31. de Bettignies, G.; Coux, O. Proteasome inhibitors: Dozens of molecules and still counting. Biochimie, 2010, 92, 1530-1545.
32. Tyndall, J. D.; Nall, T.; Fairlie, D. P. Proteases universally recognize beta strands in their active sites. Chem. Rev., 2005, 105, 973-999. (Pubitemid 40527381)
33. Madala, P. K.; Tyndall, J. D.; Nall, T.; Fairlie, D. P. Update 1 of: Proteases universally recognize beta strands in their active sites. Chem. Rev., 2010, 110, PR1-31.
34. Tyndall, J. D.; Fairlie, D. P. Macrocycles mimic the extended peptide conformation recognized by aspartic, serine, cysteine and metallo proteases. Curr. Med. Chem., 2001, 8, 893-907. (Pubitemid 32633548)
35. Braun, H. A.; Umbreen, S.; Groll, M.; Kuckelkorn, U.; Mlynarczuk, I.; Wigand, M. E.; Drung, I.; Kloetzel, P. M.; Schmidt, B. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J. Biol. Chem., 2005, 280, 28394-28401. (Pubitemid 41105738)
36. Sasse, F.; Steinmetz, H.; Schupp, T.; Petersen, F.; Memmert, K.; Hofmann, H.; Heusser, C.; Brinkmann, V.; von Matt, P.; Hofle, G.; Reichenbach, H. Argyrins, immunosuppressive cyclic peptides from myxobacteria. I. Production, isolation, physico-chemical and biological properties. J. Antibiot., 2002, 55, 543-551. (Pubitemid 34752598)
37. Vollbrecht, L.; Steinmetz, H.; Hofle, G.; Oberer, L.; Rihs, G.; Bovermann, G.; von Matt, P. Argyrins, immunosuppressive cyclic peptides from myxobacteria. II. Structure elucidation and stereochemistry. J. Antibiot., 2002, 55, 715-721. (Pubitemid 35012550)
38. Nickeleit, I.; Zender, S.; Sasse, F.; Geffers, R.; Brandes, G.; Sorensen, I.; Steinmetz, H.; Kubicka, S.; Carlomagno, T.; Menche, D.; Gutgemann, I.; Buer, J.; Gossler, A.; Manns, M. P.; Kalesse, M.; Frank, R.; Malek, N. P. Argyrin a reveals a critical role for the tumor suppressor protein p27(kip1) in mediating antitumor activities in response to proteasome inhibition. Cancer Cell, 2008, 14, 23-35. (Pubitemid 351885496)
39. Bulow, L.; Nickeleit, I.; Girbig, A. K.; Brodmann, T.; Rentsch, A.; Eggert, U.; Sasse, F.; Steinmetz, H.; Frank, R.; Carlomagno, T.; Malek, N. P.; Kalesse, M. Synthesis and biological characterization of argyrin F. ChemMedChem, 2010, 5, 832-836.
40. Stauch, B.; Simon, B.; Basile, T.; Schneider, G.; Malek, N. P.; Kalesse, M.; Carlomagno, T. Elucidation of the structure and intermolecular interactions of a reversible cyclic-peptide inhibitor of the proteasome by NMR spectroscopy and molecular modeling. Angew. Chem. Int. Ed. Engl., 2010, 49, 3934-3938.
41. Kaiser, M.; Milbradt, A. G.; Siciliano, C.; Assfalg-Machleidt, I.; Machleidt, W.; Groll, M.; Renner, C.; Moroder, L. TMC-95A analogues with endocyclic biphenyl ether group as proteasome inhibitors. Chem. Biodivers., 2004, 1, 161-173.
42. Groll, M.; Gotz, M.; Kaiser, M.; Weyher, E.; Moroder, L. TMC-95-based inhibitor design provides evidence for the catalytic versatility of the proteasome. Chem. Biol., 2006, 13, 607-614.
43. Meyer, S.; Kohler, N. G.; Joly, A. Cyclosporine A is an uncompetitive inhibitor of proteasome activity and prevents NF-kappaB activation. FEBS Lett., 1997, 413, 354-358. (Pubitemid 27353299)
44. Baldisserotto, A.; Marastoni, M.; Fiorini, S.; Pretto, L.; Ferretti, V.; Gavioli, R.; Tomatis, R. Vinyl ester-based cyclic peptide proteasome inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 1849-1854. (Pubitemid 351380904)
45. Baldisserotto, A.; Marastoni, M.; Gavioli, R.; Tomatis, R. New cyclic peptide proteasome inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 1966-1969.
46. Sekizawa, R.; Momose, I.; Kinoshita, N.; Naganawa, H.; Hamada, M.; Muraoka, Y.; Iinuma, H.; Takeuchi, T. Isolation and structural determination of phepropeptins A, B, C, and D, new proteasome inhibitors, produced by Streptomyces sp. J. Antibiot., 2001, 54, 874-881. (Pubitemid 33133798)
47. Krunic, A.; Vallat, A.; Mo, S.; Lantvit, D. D.; Swanson, S. M.; Orjala, J. Scytonemides A and B, cyclic peptides with 20S proteasome inhibitory activity from the cultured cyanobacterium Scytonema hofmanii. J. Nat. Prod., 2010, 73, 1927-1932.
48. Groll, M.; Schellenberg, B.; Bachmann, A. S.; Archer, C. R.; Huber, R.; Powell, T. K.; Lindow, S.; Kaiser, M.; Dudler, R. A plant pathogen virulence factor inhibits the eukaryotic proteasome by a novel mechanism. Nature, 2008, 452, 755-758. (Pubitemid 351521080)
49. Clerc, J.; Groll, M.; Illich, D. J.; Bachmann, A. S.; Huber, R.; Schellenberg, B.; Dudler, R.; Kaiser, M. Synthetic and structural studies on syringolin A and B reveal critical determinants of selectivity and potency of proteasome inhibition. Proc. Natl. Acad. Sci. U. S. A., 2009, 106, 6507-6512.
50. Waspi, U.; Blanc, D.; Winkler, T.; Ruedi, P.; Dudler, R. Syringolin, a novel peptide elicitor from Pseudomonas syringae pv. syringae that induces resistance to Pyricularia oryzae in rice. Mol. Plant Microbe In., 1998, 11, 727-733. (Pubitemid 28338706)
51. Waspi, U.; Hassa, P.; Staempfli, A. A.; Molleyres, L. P.; Winkler, T.; Dudler, R. Identification and structure of a family of syringolin variants: Unusual cyclic peptides from Pseudomonas syringae pv. syringae that elicit defense responses in rice. Microbiol. Res., 1999, 154, 89-93. (Pubitemid 29235484)
52. Clerc, J.; Florea, B. I.; Kraus, M.; Groll, M.; Huber, R.; Bachmann, A. S.; Dudler, R.; Driessen, C.; Overkleeft, H. S.; Kaiser, M. Syringolin A selectively labels the 20 S proteasome in murine EL4 and wild-type and bortezomib-adapted leukaemic cell lines. Chembiochem, 2009, 10, 2638-2643.
53. Clerc, J.; Schellenberg, B.; Groll, M.; Bachmann, A. S.; Huber, R.; Dudler, R.; Kaiser, M. Convergent Synthesis and Biological Evaluation of Syringolin A and Derivatives as Eukaryotic 20S Proteasome Inhibitors. Eur. J. Org. Chem., 2010, 3991-4003.
54. Clerc, J.; Li, N.; Krahn, D.; Groll, M.; Bachmann, A. S.; Florea, B. I.; Overkleeft, H. S.; Kaiser, M. The natural product hybrid of Syringolin A and Glidobactin A synergizes proteasome inhibition potency with subsite selectivity. Chem. Commun., 2011, 47, 385-387.
55. Kolodziejek, I.; Misas-Villamil, J. C.; Kaschani, F.; Clerc, J.; Gu, C.; Krahn, D.; Niessen, S.; Verdoes, M.; Willems, L. I.; Overkleeft, H. S.; Kaiser, M.; van der Hoorn, R. A. L. Proteasome Activity Imaging and Profiling Characterizes Bacterial Effector Syringolin A. Plant Physiology, 2011, 155, 477-489.
56. Anshu, A.; Thomas, S.; Agarwal, P.; Ibarra-Rivera, T. R.; Pirrung, M. C.; Schonthal, A. H. Novel proteasome-inhibitory syrbactin analogs inducing endoplasmic reticulum stress and apoptosis in hematological tumor cell lines. Biochem. Pharmacol., 2011, 82, 600-609.
57. Archer, C. R.; Koomoa, D. L.; Mitsunaga, E. M.; Clerc, J.; Shimizu, M.; Kaiser, M.; Schellenberg, B.; Dudler, R.; Bachmann, A. S. Syrbactin class proteasome inhibitor-induced apoptosis and autophagy occurs in association with p53 accumulation and Akt/PKB activation in neuroblastoma. Biochem. Pharmacol., 2010, 80, 170-178.
58. Coleman, C. S.; Rocetes, J. P.; Park, D. J.; Wallick, C. J.; Warn-Cramer, B. J.; Michel, K.; Dudler, R.; Bachmann, A. S. Syringolin A, a new plant elicitor from the phytopathogenic bacterium Pseudomonas syringae pv. syringae, inhibits the proliferation of neuroblastoma and ovarian cancer cells and induces apoptosis. Cell Prolif., 2006, 39, 599-609. (Pubitemid 44760209)
59. Oka, M.; Nishiyama, Y.; Ohta, S.; Kamei, H.; Konishi, M.; Miyaki, T.; Oki, T.; Kawaguchi, H. Glidobactins A, B and C, new antitumor antibiotics. I. Production, isolation, chemical properties and biological activity. J. Antibiot., 1988, 41, 1331-1337. (Pubitemid 18259415)
60. Oka, M.; Yaginuma, K.; Numata, K.; Konishi, M.; Oki, T.; Kawaguchi, H. Glidobactins A, B and C, new antitumor antibiotics. II. Structure elucidation. J. Antibiot., 1988, 41, 1338-1350. (Pubitemid 18259416)
61. Oka, M.; Ohkuma, H.; Kamei, H.; Konishi, M.; Oki, T.; Kawaguchi, H. Glidobactins D, E, F, G and H; minor components of the antitumor antibiotic glidobactin. J. Antibiot., 1988, 41, 1906-1909. (Pubitemid 19010360)
62. Oka, M.; Numata, K.; Nishiyama, Y.; Kamei, H.; Konishi, M.; Oki, T.; Kawaguchi, H. Chemical modification of the antitumor antibiotic glidobactin. J. Antibiot., 1988, 41, 1812-1822. (Pubitemid 19010349)
63. Numata, K.; Oka, M.; Nakakita, Y.; Murakami, T.; Miyaki, T.; Konishi, M.; Oki, T.; Kawaguchi, H. Enzymatic formation of glidobactamine: A peptide nucleus of glidobactins A, B and C, new lipopeptide antitumor antibiotics. J. Antibiot., 1988, 41, 1351-1357. (Pubitemid 18259417)
64. Ohnuma, T.; Obata, R.; Yamasaki, T.; Kamei, H.; Naito, T. Chemical Modification of Glidobactin-α, a Novel Antitumor Antibiotic. J. Pharm. Sci., 1987, 76, S167-S167.
65. Shoji, J.; Hinoo, H.; Kato, T.; Hattori, T.; Hirooka, K.; Tawara, K.; Shiratori, O.; Terui, Y. Isolation of cepafungins I, II and III from Pseudomonas species. J. Antibiot., 1990, 43, 783-787. (Pubitemid 20239819)
66. Terui, Y.; Nishikawa, J.; Hinoo, H.; Kato, T.; Shoji, J. Structures of cepafungins I, II and III. J. Antibiot., 1990, 43, 788-795. (Pubitemid 20239820)
67. Imker, H. J.; Walsh, C. T.; Wuest, W. M. SylC catalyzes ureido-bond formation during biosynthesis of the proteasome inhibitor syringolin A. J. Am. Chem. Soc., 2009, 131, 18263-18265.
68. Imker, H. J.; Krahn, D.; Clerc, J.; Kaiser, M.; Walsh, C. T. N-acylation during glidobactin biosynthesis by the tridomain nonribosomal peptide synthetase module GlbF. Chem. Biol., 2010, 17, 1077-1083.
69. Ramel, C.; Tobler, M.; Meyer, M.; Bigler, L.; Ebert, M. O.; Schellenberg, B.; Dudler, R. Biosynthesis of the proteasome inhibitor syringolin A: The ureido group joining two amino acids originates from bicarbonate. Bmc Biochemistry, 2009, 10.
70. Wuest, W. M.; Krahn, D.; Kaiser, M.; Walsh, C. T. Enzymatic timing and tailoring of macrolactamization in syringolin biosynthesis. Org. Lett., 2011, 13, 4518-4521.
71. Bhat, U. G.; Halasi, M.; Gartel, A. L. FoxM1 Is a General Target for Proteasome Inhibitors. PLoS One, 2009, 4, e6593.
72. Pandit, B.; Bhat, U. G.; Gartel, A. L. Proteasome inhibitory activity of thiazole antibiotics. Cancer Biol. Ther., 2011, 11, 43-47.
73. Pandit, B.; Gartel, A. L. Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. Am. J. Pathol., 2011, 178, 355-360.
74. Schoof, S.; Pradel, G.; Aminake, M. N.; Ellinger, B.; Baumann, S.; Potowski, M.; Najajreh, Y.; Kirschner, M.; Arndt, H. D. Antiplasmodial thiostrepton derivatives: Proteasome inhibitors with a dual mode of action. Angew. Chem. Int. Ed. Engl., 2010, 49, 3317-3321.
75. Aminake, M. N.; Schoof, S.; Sologub, L.; Leubner, M.; Kirschner, M.; Arndt, H. D.; Pradel, G. Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast. Antimicrob. Agents Chemother., 2011, 55, 1338-1348.
76. Koguchi, Y.; Kohno, J.; Nishio, M.; Takahashi, K.; Okuda, T.; Ohnuki, T.; Komatsubara, S. TMC-95A, B, C, and D, novel proteasome inhibitors produced by Apiospora montagnei Sacc. TC 1093. Taxonomy, production, isolation, and biological activities. J. Antibiot., 2000, 53, 105-109. (Pubitemid 30135865)
77. Kohno, J.; Koguchi, Y.; Nishio, M.; Nakao, K.; Kuroda, M.; Shimizu, R.; Ohnuki, T.; Komatsubara, S. Structures of TMC-95A-D: Novel proteasome inhibitors from Apiospora montagnei sacc. TC 1093. J. Org. Chem., 2000, 65, 990-995. (Pubitemid 30117368)
78. Inoue, M.; Zhai, H.; Sakazaki, H.; Furuyama, H.; Fukuyama, Y.; Hirama, M. TMC-95A, a reversible proteasome inhibitor, induces neurite outgrowth in PC12 cells. Bioorg. Med. Chem. Lett., 2004, 14, 663-665. (Pubitemid 38114848)
79. Groll, M.; Koguchi, Y.; Huber, R.; Kohno, J. Crystal structure of the 20 S proteasome:TMC-95A complex: A non-covalent proteasome inhibitor. J. Mol. Biol., 2001, 311, 543-548. (Pubitemid 32816588)
80. Kaiser, M.; Groll, M.; Renner, C.; Huber, R.; Moroder, L. The core structure of TMC-95A is a promising lead for reversible proteasome inhibition. Angew. Chem. Int. Ed. Engl., 2002, 41, 780-783. (Pubitemid 34218522)
81. Kaiser, M.; Groll, M.; Siciliano, C.; Assfalg-Machleidt, I.; Weyher, E.; Kohno, J.; Milbradt, A. G.; Renner, C.; Huber, R.; Moroder, L. Binding mode of TMC-95A analogues to eukaryotic 20S proteasome. Chembiochem, 2004, 5, 1256-1266. (Pubitemid 39297256)
82. Kaiser, M.; Siciliano, C.; Assfalg-Machleidt, I.; Groll, M.; Milbradt, A. G.; Moroder, L. Synthesis of a TMC-95A ketomethylene analogue by cyclization via intramolecular Suzuki coupling. Org. Lett., 2003, 5, 3435-3437. (Pubitemid 37487432)
83. Yang, Z. Q.; Kwok, B. H.; Lin, S.; Koldobskiy, M. A.; Crews, C. M.; Danishefsky, S. J. Simplified synthetic TMC-95A/B analogues retain the potency of proteasome inhibitory activity. Chembiochem, 2003, 4, 508-513. (Pubitemid 36749621)
84. Basse, N.; Piguel, S.; Papapostolou, D.; Ferrier-Berthelot, A.; Richy, N.; Pagano, M.; Sarthou, P.; Sobczak-Thepot, J.; Reboud-Ravaux, M.; Vidal, J. Linear TMC-95-based proteasome inhibitors. J. Med. Chem., 2007, 50, 2842-2850. (Pubitemid 46980854)
85. Groll, M.; Gallastegui, N.; Marechal, X.; Le Ravalec, V.; Basse, N.; Richy, N.; Genin, E.; Huber, R.; Moroder, L.; Vidal, J.; Reboud-Ravaux, M. 20S proteasome inhibition: Designing noncovalent linear peptide mimics of the natural product TMC-95A. ChemMedChem, 2010, 5, 1701-1705.
86. Coste, A.; Couty, F.; Evano, G. TMC-95A-D and analogues: Chemistry and biology. Comptes Rendus Chimie, 11, 1544-1573.